BioCentury | Jan 7, 2013
Company News

CytImmune, AstraZeneca deal

...AstraZeneca partnered with CytImmune to evaluate the feasibility of combining an undisclosed preclinical cancer compound from...
...feasibility of combining an undisclosed preclinical cancer compound from the pharma with CytImmune's CYT-6091 . CytImmune...
...tumors. The partners, which declined to provide details, announced the deal on Dec. 27, 2012. CytImmune Sciences Inc....
BioCentury | Dec 28, 2012
Company News

AZN, CytImmune in cancer deal

...AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered with CytImmune Sciences Inc. (Rockville, Md.) to evaluate the feasibility of combining an...
...feasibility of combining an undisclosed preclinical cancer compound from the pharma with CytImmune's CYT-6091 . CytImmune...
BioCentury | Feb 4, 2010
Tools & Techniques

Nanoparticle drug delivery heats up

...much more efficient targeting system" than conventional RGD peptides. Lawrence Tamarkin, president and CEO of CytImmune Sciences Inc....
...Ruoslahti's internalizable RGD variant "goes a little further than the conventional RGD" toward this goal. CytImmune's...
...and Institutions Mentioned Abraxis BioScience Inc. (NASDAQ:ABII), Los Angeles, Calif. Celsion Corp. (NASDAQ:CLSN), Columbia, Md. CytImmune Sciences Inc....
BioCentury | Nov 13, 2008
Cover Story

Prostate-bound nanoparticles

...tumor. "Conceptually, that's what you want to do," Lawrence Tamarkin, president, CEO and cofounder of CytImmune Sciences Inc....
...have a water shield to protect the molecule and a molecule to target the tumor." CytImmune...
...aptamer triggers an immune response, we will have to switch it out for another one." CytImmune's...
BioCentury | Feb 21, 2008
Tools & Techniques

Serial killing nanocarriers

...of hematology/oncology and otolaryngology. Another unanswered question, according to Larry Tamarkin, president and CEO of CytImmune Sciences Inc....
...delivered via nanocarrier is more efficacious than a standard dose of chemotherapeutic delivered via I.V." CytImmune's...
...release of doxorubicin from heat-sensitive liposomes. Companies and Institutions Mentioned Celsion Corp. (AMEX:CLN), Columbia, Md. CytImmune Sciences Inc....
BioCentury | Jun 11, 2007
Clinical News

CYT-6091: Preliminary Phase I data

...mg/m 2. Data were presented at the American Society of Clinical Oncology meeting in Chicago. CytImmune Sciences Inc....
BioCentury | Jun 5, 2006
Clinical News

CYT-6091: Phase I started

...CytImmune began an open-label, dose-escalation, U.S. Phase I trial in up to 42 patients. CytImmune Sciences Inc....
BioCentury | Mar 27, 2006
Company News

CytImmune board of directors update

CytImmune Sciences Inc. , Rockville, Md. Business: Cancer Appointed: Kenneth White, retired director of finance and pharmaceutical business development at Bristol-Myers Squibb Co. WIR Staff cancer...
BioCentury | Mar 27, 2006
Company News

CytImmune management update

CytImmune Sciences Inc. , Rockville, Md. Business: Cancer Hired: Mitchell Marder as VP and general counsel, formerly a partner at Katten Muchin Rosenman LLP WIR Staff...
BioCentury | Feb 21, 2005
Company News

CytImmune, Boehringer Ingelheim deal

...Boehringer's Boehringer Ingelheim Animal Health (St. Joseph, Mo.) subsidiary licensed CytImmune's nanoparticle drug delivery technology to...
...nanoparticle drug delivery technology to develop, produce and market tumor-targeted cancer therapeutics for veterinary use. CytImmune Sciences Inc....
Items per page:
1 - 10 of 16
BioCentury | Jan 7, 2013
Company News

CytImmune, AstraZeneca deal

...AstraZeneca partnered with CytImmune to evaluate the feasibility of combining an undisclosed preclinical cancer compound from...
...feasibility of combining an undisclosed preclinical cancer compound from the pharma with CytImmune's CYT-6091 . CytImmune...
...tumors. The partners, which declined to provide details, announced the deal on Dec. 27, 2012. CytImmune Sciences Inc....
BioCentury | Dec 28, 2012
Company News

AZN, CytImmune in cancer deal

...AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered with CytImmune Sciences Inc. (Rockville, Md.) to evaluate the feasibility of combining an...
...feasibility of combining an undisclosed preclinical cancer compound from the pharma with CytImmune's CYT-6091 . CytImmune...
BioCentury | Feb 4, 2010
Tools & Techniques

Nanoparticle drug delivery heats up

...much more efficient targeting system" than conventional RGD peptides. Lawrence Tamarkin, president and CEO of CytImmune Sciences Inc....
...Ruoslahti's internalizable RGD variant "goes a little further than the conventional RGD" toward this goal. CytImmune's...
...and Institutions Mentioned Abraxis BioScience Inc. (NASDAQ:ABII), Los Angeles, Calif. Celsion Corp. (NASDAQ:CLSN), Columbia, Md. CytImmune Sciences Inc....
BioCentury | Nov 13, 2008
Cover Story

Prostate-bound nanoparticles

...tumor. "Conceptually, that's what you want to do," Lawrence Tamarkin, president, CEO and cofounder of CytImmune Sciences Inc....
...have a water shield to protect the molecule and a molecule to target the tumor." CytImmune...
...aptamer triggers an immune response, we will have to switch it out for another one." CytImmune's...
BioCentury | Feb 21, 2008
Tools & Techniques

Serial killing nanocarriers

...of hematology/oncology and otolaryngology. Another unanswered question, according to Larry Tamarkin, president and CEO of CytImmune Sciences Inc....
...delivered via nanocarrier is more efficacious than a standard dose of chemotherapeutic delivered via I.V." CytImmune's...
...release of doxorubicin from heat-sensitive liposomes. Companies and Institutions Mentioned Celsion Corp. (AMEX:CLN), Columbia, Md. CytImmune Sciences Inc....
BioCentury | Jun 11, 2007
Clinical News

CYT-6091: Preliminary Phase I data

...mg/m 2. Data were presented at the American Society of Clinical Oncology meeting in Chicago. CytImmune Sciences Inc....
BioCentury | Jun 5, 2006
Clinical News

CYT-6091: Phase I started

...CytImmune began an open-label, dose-escalation, U.S. Phase I trial in up to 42 patients. CytImmune Sciences Inc....
BioCentury | Mar 27, 2006
Company News

CytImmune board of directors update

CytImmune Sciences Inc. , Rockville, Md. Business: Cancer Appointed: Kenneth White, retired director of finance and pharmaceutical business development at Bristol-Myers Squibb Co. WIR Staff cancer...
BioCentury | Mar 27, 2006
Company News

CytImmune management update

CytImmune Sciences Inc. , Rockville, Md. Business: Cancer Hired: Mitchell Marder as VP and general counsel, formerly a partner at Katten Muchin Rosenman LLP WIR Staff...
BioCentury | Feb 21, 2005
Company News

CytImmune, Boehringer Ingelheim deal

...Boehringer's Boehringer Ingelheim Animal Health (St. Joseph, Mo.) subsidiary licensed CytImmune's nanoparticle drug delivery technology to...
...nanoparticle drug delivery technology to develop, produce and market tumor-targeted cancer therapeutics for veterinary use. CytImmune Sciences Inc....
Items per page:
1 - 10 of 16